molecular therapeutic drug subject research potential treatment cancer according journal clinical oncology subcutaneously sc administered nonapeptide thrombospondin following inconclusive phase clinical trials phase ii study treatment metastatic melanoma failed reach primary endpoint resulting termination study three twentyone patients reached primary endpoint progressionfree survival weeks three patients remained progressionfree weeks however biomarker data collected study showed decrease vegfc circulating endothelial cells counts maximum tolerated dose still established study could consider higher dose andor combination